Uroflow Mechanism of Action

Pharmacology: Pharmacodynamics: Tamsulosin is a member of sulfamoylphenethylamine-derivative substances. Tamsulosin as well as other drugs in the same pharmacologic class such as doxazosin, prazosin and terazosin are capable to reduce urinary obstruction, improve urinary flow rates and relieve  obstructive manifestations associated with BPH. Tamsulosin has a 7-38 times greater affinity for alpha_1a receptors located in vascular smooth muscles (e.g., prostate muscle), then alpha_1B receptors located in vascular smooth muscles. Blocking of such receptors is associated with decreased resistance of urinary flow, particularly in patients with symptomatic benign prostatic hyperplasia (BPH). In addition, such selectivity of tamsulosin results in reduced incidence of adverse cardiovascular events (e.g., syncope, dizziness, orthostatic hypotension).
Pharmacokinetics: Absorption: Tamsulosin has good oral bioavailability and reach the peak concentration at 4-5 hours after administration in fasting state or 6-7 hours in fed state for plain formulation. However, the rate and extent of absorption of Uroflow which are modified release tablets are not affected by food.
Distribution: Tamsulosin is widely distributed in various tissue. 94% to 99% of tamsulosin is bound to alpha-1 acid glycoprotein.
Metabolism and Elimination: Tamsulosin is extensively metabolized by hepatic CYP3A4 and 2D6 enzyme systems. The metabolites undergo conjugation to glucoronide or sulfate, then are excreted by urination. Only 21% of absorbed tamsulosin is excreted in the feces. Elimination half-life of tamsulosin is approximately 9 to 15 hours in healthy populations.